{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:45:28Z","timestamp":1793285128392,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2011,4,26]],"date-time":"2011-04-26T00:00:00Z","timestamp":1303776000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1007\/s00125-011-2158-9","type":"journal-article","created":{"date-parts":[[2011,4,25]],"date-time":"2011-04-25T12:03:35Z","timestamp":1303733015000},"page":"2152-2163","source":"Crossref","is-referenced-by-count":99,"title":["Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets"],"prefix":"10.1007","volume":"54","author":[{"given":"J. M.","family":"Luther","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. T.","family":"Kreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Brissova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. T.","family":"Whitfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. H.","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,26]]},"reference":[{"key":"2158_CR1","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/en.141.10.3871","volume":"141","author":"R Rocha","year":"2000","unstructured":"Rocha R, Stier CT Jr, Kifor I et al (2000) Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141:3871\u20133878","journal-title":"Endocrinology"},{"key":"2158_CR2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0952-3278(99)80020-9","volume":"60","author":"TL Goodfriend","year":"1999","unstructured":"Goodfriend TL, Egan BM, Kelley DE (1999) Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids 60:401\u2013405","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"2158_CR3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/01.HYP.0000231338.41548.fc","volume":"48","author":"M Bochud","year":"2006","unstructured":"Bochud M, Nussberger J, Bovet P et al (2006) Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 48:239\u2013245","journal-title":"Hypertension"},{"key":"2158_CR4","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1161\/CIRCULATIONAHA.107.708537","volume":"116","author":"E Ingelsson","year":"2007","unstructured":"Ingelsson E, Pencina MJ, Tofler GH et al (2007) Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 116:984\u2013992","journal-title":"Circulation"},{"key":"2158_CR5","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJM198104163041602","volume":"304","author":"ML Tuck","year":"1981","unstructured":"Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M (1981) The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 304:930\u2013933","journal-title":"N Engl J Med"},{"key":"2158_CR6","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1161\/01.HYP.0000113294.06704.64","volume":"43","author":"TL Goodfriend","year":"2004","unstructured":"Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K (2004) Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 43:358\u2013363","journal-title":"Hypertension"},{"key":"2158_CR7","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1056\/NEJM196511182732106","volume":"273","author":"JW Conn","year":"1965","unstructured":"Conn JW (1965) Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med 273:1135\u20131143","journal-title":"N Engl J Med"},{"key":"2158_CR8","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.2337\/dc07-0525","volume":"30","author":"G Colussi","year":"2007","unstructured":"Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA (2007) Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 30:2349\u20132354","journal-title":"Diabetes Care"},{"key":"2158_CR9","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1210\/jc.2006-0736","volume":"91","author":"C Catena","year":"2006","unstructured":"Catena C, Lapenna R, Baroselli S et al (2006) Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 91:3457\u20133463","journal-title":"J Clin Endocrinol Metab"},{"key":"2158_CR10","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/nature05482","volume":"444","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840\u2013846","journal-title":"Nature"},{"key":"2158_CR11","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1097\/HJH.0b013e3282861fa4","volume":"25","author":"LM Mosso","year":"2007","unstructured":"Mosso LM, Carvajal CA, Maiz A et al (2007) A possible association between primary aldosteronism and a lower \u03b2-cell function. J Hypertens 25:2125\u20132130","journal-title":"J Hypertens"},{"key":"2158_CR12","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa065061","volume":"355","author":"J Bosch","year":"2006","unstructured":"Bosch J, Yusuf S, Gerstein HC et al (2006) Effect of ramipril on the incidence of diabetes. N Engl J Med 355:1551\u20131562","journal-title":"N Engl J Med"},{"key":"2158_CR13","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1001121","volume":"362","author":"JJ McMurray","year":"2010","unstructured":"McMurray JJ, Holman RR, Haffner SM et al (2010) Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1477\u20131490","journal-title":"N Engl J Med"},{"key":"2158_CR14","doi-asserted-by":"crossref","first-page":"F61","DOI":"10.1152\/ajprenal.00257.2005","volume":"290","author":"N Makhanova","year":"2006","unstructured":"Makhanova N, Lee G, Takahashi N et al (2006) Kidney function in mice lacking aldosterone. Am J Physiol Renal Physiol 290:F61\u2013F69","journal-title":"Am J Physiol Renal Physiol"},{"key":"2158_CR15","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1210\/en.2008-1296","volume":"150","author":"JM Luther","year":"2009","unstructured":"Luther JM, Wang Z, Ma J, Makhanova N, Kim HS, Brown NJ (2009) Endogenous aldosterone contributes to acute angiotensin II-stimulated plasminogen activator inhibitor-1 and preproendothelin-1 expression in heart but not aorta. Endocrinology 150:2229\u20132236","journal-title":"Endocrinology"},{"key":"2158_CR16","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1210\/en.2004-1102","volume":"146","author":"G Lee","year":"2005","unstructured":"Lee G, Makhanova N, Caron K et al (2005) Homeostatic responses in the adrenal cortex to the absence of aldosterone in mice. Endocrinology 146:2650\u20132656","journal-title":"Endocrinology"},{"key":"2158_CR17","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2337\/diabetes.55.02.06.db05-0686","volume":"55","author":"JE Ayala","year":"2006","unstructured":"Ayala JE, Bracy DP, McGuinness OP, Wasserman DH (2006) Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 55:390\u2013397","journal-title":"Diabetes"},{"key":"2158_CR18","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1210\/en.2004-0465","volume":"145","author":"PT Fueger","year":"2004","unstructured":"Fueger PT, Hess HS, Bracy DP et al (2004) Regulation of insulin-stimulated muscle glucose uptake in the conscious mouse: role of glucose transport is dependent on glucose phosphorylation capacity. Endocrinology 145:4912\u20134916","journal-title":"Endocrinology"},{"key":"2158_CR19","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.2337\/db07-1615","volume":"57","author":"ED Berglund","year":"2008","unstructured":"Berglund ED, Li CY, Poffenberger G et al (2008) Glucose metabolism in vivo in four commonly used inbred mouse strains. Diabetes 57:1790\u20131799","journal-title":"Diabetes"},{"key":"2158_CR20","doi-asserted-by":"crossref","first-page":"11225","DOI":"10.1074\/jbc.M111272200","volume":"277","author":"M Brissova","year":"2002","unstructured":"Brissova M, Shiota M, Nicholson WE et al (2002) Reduction in pancreatic transcription factor PDX-1 impairs glucose-stimulated insulin secretion. J Biol Chem 277:11225\u201311232","journal-title":"J Biol Chem"},{"key":"2158_CR21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1210\/endo-127-1-126","volume":"127","author":"J Miyazaki","year":"1990","unstructured":"Miyazaki J, Araki K, Yamato E et al (1990) Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology 127:126\u2013132","journal-title":"Endocrinology"},{"key":"2158_CR22","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1161\/01.CIR.0000071081.35693.9A","volume":"107","author":"NJ Brown","year":"2003","unstructured":"Brown NJ (2003) Eplerenone: cardiovascular protection. Circulation 107:2512\u20132518","journal-title":"Circulation"},{"key":"2158_CR23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","volume":"217","author":"SM Garthwaite","year":"2004","unstructured":"Garthwaite SM, McMahon EG (2004) The evolution of aldosterone antagonists. Mol Cell Endocrinol 217:27\u201331","journal-title":"Mol Cell Endocrinol"},{"key":"2158_CR24","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1210\/en.2005-0860","volume":"147","author":"CE Gomez-Sanchez","year":"2006","unstructured":"Gomez-Sanchez CE, de Rodriguez AF, Romero DG et al (2006) Development of a panel of monoclonal antibodies against the mineralocorticoid receptor. Endocrinology 147:1343\u20131348","journal-title":"Endocrinology"},{"key":"2158_CR25","first-page":"723","volume":"11","author":"S Uehara","year":"2003","unstructured":"Uehara S, Tsuchida M, Kanno T, Sasaki M, Nishikibe M, Fukamizu A (2003) Late-onset obesity in mice transgenic for the human renin gene. Int J Mol Med 11:723\u2013727","journal-title":"Int J Mol Med"},{"key":"2158_CR26","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/HYPERTENSIONAHA.108.124966","volume":"53","author":"P Gratze","year":"2009","unstructured":"Gratze P, Boschmann M, Dechend R et al (2009) Energy metabolism in human renin-gene transgenic rats: does renin contribute to obesity? Hypertension 53:516\u2013523","journal-title":"Hypertension"},{"key":"2158_CR27","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1161\/HYPERTENSIONAHA.107.093955","volume":"50","author":"H Hitomi","year":"2007","unstructured":"Hitomi H, Kiyomoto H, Nishiyama A et al (2007) Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 50:750\u2013755","journal-title":"Hypertension"},{"key":"2158_CR28","doi-asserted-by":"crossref","first-page":"E110","DOI":"10.1152\/ajpendo.00258.2007","volume":"295","author":"G Lastra","year":"2008","unstructured":"Lastra G, Whaley-Connell A, Manrique C et al (2008) Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab 295:E110\u2013E116","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2158_CR29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s001250050880","volume":"41","author":"PO Carlsson","year":"1998","unstructured":"Carlsson PO, Berne C, Jansson L (1998) Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 41:127\u2013133","journal-title":"Diabetologia"},{"key":"2158_CR30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1677\/joe.0.1600013","volume":"160","author":"PS Leung","year":"1999","unstructured":"Leung PS, Chan WP, Wong TP, Sernia C (1999) Expression and localization of the renin-angiotensin system in the rat pancreas. J Endocrinol 160:13\u201319","journal-title":"J Endocrinol"},{"key":"2158_CR31","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2165\/00003495-200464220-00004","volume":"64","author":"AJ Scheen","year":"2004","unstructured":"Scheen AJ (2004) Prevention of type 2 diabetes mellitus through inhibition of the renin\u2013angiotensin system. Drugs 64:2537\u20132565","journal-title":"Drugs"},{"key":"2158_CR32","first-page":"21","volume":"108","author":"G Sindelka","year":"2000","unstructured":"Sindelka G, Widimsky J, Haas T, Prazny M, Hilgertova J, Skrha J (2000) Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment. Exp Clin Endocrinol Diabetes 108:21\u201325","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"2158_CR33","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1046\/j.1365-2362.2003.01236.x","volume":"33","author":"A Voiculescu","year":"2003","unstructured":"Voiculescu A, Hollenbeck M, Kutkuhn B, Grabensee B, Plum J (2003) Successful treatment of renovascular hypertension has no effect on insulin sensitivity. Eur J Clin Investig 33:848\u2013854","journal-title":"Eur J Clin Investig"},{"key":"2158_CR34","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/db07-0954","volume":"57","author":"A Festa","year":"2008","unstructured":"Festa A, Williams K, Hanley AJ, Haffner SM (2008) Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 57:1638\u20131644","journal-title":"Diabetes"},{"key":"2158_CR35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF00456122","volume":"29","author":"J Pierluissi","year":"1986","unstructured":"Pierluissi J, Navas FO, Ashcroft SJ (1986) Effect of adrenal steroids on insulin release from cultured rat islets of Langerhans. Diabetologia 29:119\u2013121","journal-title":"Diabetologia"},{"key":"2158_CR36","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1210\/me.2007-0568","volume":"22","author":"JC Chuang","year":"2008","unstructured":"Chuang JC, Cha JY, Garmey JC, Mirmira RG, Repa JJ (2008) Research resource: nuclear hormone receptor expression in the endocrine pancreas. Mol Endocrinol 22:2353\u20132363","journal-title":"Mol Endocrinol"},{"key":"2158_CR37","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1161\/CIRCRESAHA.109.196576","volume":"105","author":"CA Lemarie","year":"2009","unstructured":"Lemarie CA, Simeone SM, Nikonova A et al (2009) Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res 105:852\u2013859","journal-title":"Circ Res"},{"key":"2158_CR38","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/ndt\/gfg265","volume":"18","author":"B Boldyreff","year":"2003","unstructured":"Boldyreff B, Wehling M (2003) Non-genomic actions of aldosterone: mechanisms and consequences in kidney cells. Nephrol Dial Transplant 18:1693\u20131695","journal-title":"Nephrol Dial Transplant"},{"key":"2158_CR39","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1210\/jc.82.11.3859","volume":"82","author":"G Hirasawa","year":"1997","unstructured":"Hirasawa G, Sasano H, Ki T et al (1997) Colocalization of 11\u03b2-hydroxysteroid dehydrogenase type II and mineralocorticoid receptor in human epithelia. J Clin Endocrinol Metab 82:3859\u20133863","journal-title":"J Clin Endocrinol Metab"},{"key":"2158_CR40","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.steroids.2004.05.005","volume":"69","author":"R Losel","year":"2004","unstructured":"Losel R, Schultz A, Boldyreff B, Wehling M (2004) Rapid effects of aldosterone on vascular cells: clinical implications. Steroids 69:575\u2013578","journal-title":"Steroids"},{"key":"2158_CR41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00424-008-0616-0","volume":"458","author":"M Gekle","year":"2009","unstructured":"Gekle M, Grossmann C (2009) Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly? Pflugers Arch 458:231\u2013246","journal-title":"Pflugers Arch"},{"key":"2158_CR42","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrneph.2010.30","volume":"6","author":"M Briet","year":"2010","unstructured":"Briet M, Schiffrin EL (2010) Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 6:261\u2013273","journal-title":"Nat Rev Nephrol"},{"key":"2158_CR43","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00424-010-0862-9","volume":"460","author":"G Drews","year":"2010","unstructured":"Drews G, Krippeit-Drews P, Dufer M (2010) Oxidative stress and beta-cell dysfunction. Pflugers Arch 460:703\u2013718","journal-title":"Pflugers Arch."},{"key":"2158_CR44","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1096\/fj.06-7970com","volume":"21","author":"M Caprio","year":"2007","unstructured":"Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro MC (2007) Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 21:2185\u20132194","journal-title":"FASEB J"},{"key":"2158_CR45","first-page":"755","volume":"8","author":"K Shimamoto","year":"1994","unstructured":"Shimamoto K, Shiiki M, Ise T et al (1994) Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism? J Hum Hypertens 8:755\u2013759","journal-title":"J Hum Hypertens"},{"key":"2158_CR46","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ahj.2004.12.005","volume":"150","author":"MH Weinberger","year":"2005","unstructured":"Weinberger MH, White WB, Ruilope LM et al (2005) Effects of eplerenone vs losartan in patients with low-renin hypertension. Am Heart J 150:426\u2013433","journal-title":"Am Heart J"},{"key":"2158_CR47","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s00125-008-0972-5","volume":"51","author":"K Swaminathan","year":"2008","unstructured":"Swaminathan K, Davies J, George J, Rajendra NS, Morris AD, Struthers AD (2008) Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia 51:762\u2013768","journal-title":"Diabetologia"},{"key":"2158_CR48","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/jmv.21572","volume":"81","author":"Y Arase","year":"2009","unstructured":"Arase Y, Suzuki F, Suzuki Y et al (2009) Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C. J Med Virol 81:1584\u20131590","journal-title":"J Med Virol"},{"key":"2158_CR49","doi-asserted-by":"crossref","first-page":"503","DOI":"10.33549\/physiolres.930298","volume":"52","author":"B Strauch","year":"2003","unstructured":"Strauch B, Widimsky J, Sindelka G, Skrha J (2003) Does the treatment of primary hyperaldosteronism influence glucose tolerance? Physiol Res 52:503\u2013506","journal-title":"Physiol Res"},{"key":"2158_CR50","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","volume":"56","author":"L Amar","year":"2010","unstructured":"Amar L, Azizi M, Menard J, Peyrard S, Watson C, Plouin PF (2010) Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 56:831\u2013838","journal-title":"Hypertension"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-011-2158-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-011-2158-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-011-2158-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T06:45:07Z","timestamp":1712385907000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-011-2158-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,26]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["2158"],"URL":"https:\/\/doi.org\/10.1007\/s00125-011-2158-9","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,26]]}}}